EIKN
NASDAQEikon Therapeutics Inc.
Price$8.37-0.48 (-5.43%)
01:45 PM07:45 PM
News · 26 weeks38-17%
2025-12-142026-06-07
Mix1490d
- SEC Filings6(43%)
- Other6(43%)
- Offering1(7%)
- Leadership1(7%)
Latest news
25 items- SECEikon Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of DirectorsMILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon's Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board. "Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer of Eikon. "Her per
- SECEikon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical OncologyTeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued developmentPhase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several
- PREikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical OncologyPresentations to cover progress across Eikon's most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet me
- SECSEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
- SECSEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
- SECSEC Form 10-Q filed by Eikon Therapeutics Inc.10-Q - Eikon Therapeutics, Inc. (0001861123) (Filer)
- SECEikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical UpdatesMaintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitorSix abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company's lead programs including new safety, tolerability, and efficacy data Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking (SMT) to advance
- SECSEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)
- SECEikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate UpdatesClosed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 trial of EIK1001 in first-line treatment of stage 4 non-small cell lung cancer MILLBRAE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced fourth quarter and full year 2025 financial results and provided corporate updates. "2025 was an important year of progress for Eikon's business and clinical programs," said Roger M. Perlmutter, M.D., Ph.D., Chief Execut
- SECSEC Form 10-K filed by Eikon Therapeutics Inc.10-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Klobuchar Michael A4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Director Huffines Robert Luther4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Director Frazier Kenneth C4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Officer Perlmutter Roger M4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Officer Thorner Benjamin Bruno4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Baynes Roy D.4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Bowie Alfred Lloyd Jr.4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Eikon TherapeuticsCantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight
- ANALYSTMorgan Stanley initiated coverage on Eikon Therapeutics with a new price targetMorgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00
- ANALYSTAnalyst initiated coverage on Eikon Therapeutics with a new price targetAnalyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00
- ANALYSTMizuho initiated coverage on Eikon Therapeutics with a new price targetMizuho initiated coverage of Eikon Therapeutics with a rating of Outperform and set a new price target of $26.00
EIKN FAQ
6 questionsWhere does EIKN stock trade?
Eikon Therapeutics Inc. (EIKN) is listed on NASDAQ.What sector and industry is EIKN in?
Eikon Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Eikon Therapeutics Inc. go public?
Eikon Therapeutics Inc. (EIKN) completed its IPO in 2026.What are analysts saying about EIKN?
Eikon Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-03-02. Recent price targets range from $700.00 to $3400.00.What companies are similar to EIKN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare EIKN side-by-side with any of them on Quantisnow.How can I track EIKN on Quantisnow?
Quantisnow aggregates Eikon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EIKN to receive live email and push alerts on every new disclosure.